2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. Interleukin Related Ligand

Interleukin Related Ligand

Interleukin Related Isoform Comparison

Interleukin Related Ligands (9):

Cat. No. Product Name Effect Purity
  • HY-P11287A
    DOTA-Pep-1L TFA
    		Ligand 98.60%
    DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research.
  • HY-P990708
    Bizaxofusp
    		Ligand
    Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer.
  • HY-P991146
    Lecankitug
    		Ligand 98%
    Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
  • HY-P991144
    Lasrekibart
    		Ligand
    Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma.
  • HY-P991129
    Crusekitug
    		Ligand
    Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
  • HY-P11287
    DOTA-Pep-1L
    		Ligand
    DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research.
  • HY-P992074
    Zemlikafusp alfa
    		Ligand
    Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
  • HY-176555
    Z169667518
    		Ligand
    Z169667518 is a ligand of IL-6. Z169667518 can inhibit IL-6-induced STAT3 reporter activity with an IC50 of 2.7 µM. Z169667518 can be used in the research of IL-6-related diseases.
  • HY-N9086A
    (rac)-Poriol
    		Ligand
    (rac)-Poriol (5,7,4'-Trihydroxy-6-methylflavanone) exhibits antioxidant activity, and scavenges free radical DPPH with an IC50 of 0.18 µg/mL. (rac)-Poriol inhibits the LPS (HY-D1056)-induced NO generation in RAW264.7 (98.35% inhibition rate at 10 μM), and exhibits anti-inflammatory activity. (rac)-Poriol exhibits good binding affinity with iNOS, COX-1, COX-2, TNF-α, and IL-1β.